328918-84-9

Basic information

• Product Name: 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol
• Synonyms: 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol
• CAS NO: 328918-84-9
• Molecular Weight: 282.137
• Mol File: 328918-84-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol(328918-84-9)
• EPA Substance Registry System: 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol(328918-84-9)

Safety Data

• Hazardous Substances Data: 328918-84-9(Hazardous Substances Data)

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-80-5 4,5-dimethyl-2-(4-bromophenyl)-oxazole oxide 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 

Downstream Products

• 401468-49-3 3-{4-[2-(2-Biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]-phenyl}-2-methyl-2-phenoxypropionic acid 
• 698347-45-4 3-{4-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]phenyl}-2-methyl-2-phenoxypropionic acid ethyl ester 
• 853260-27-2 3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-p-tolyloxy-propionic acid ethyl ester 
• 401468-89-1 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid 
• 853260-43-2 3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-tert-butyl-phenoxy)-2-methyl-propionic acid ethyl ester 
• 328918-98-5 toluene-4-sulfonic acid 2-[2-(3-bromophenyl)-5-methyloxazol-4-yl]ethyl Ester 
• 876616-93-2 2-[2-(4'-methanesulfonyl-biphenyl-4-yl)-5-methyl-oxazol-4-yl]-ethanol 
• 876617-08-2 2-(4-bromo-phenyl)-4-(2-iodo-ethyl)-5-methyl-oxazoIe 
• 876616-96-5 methanesulfonic acid 2-[2-(4-bromo-phenyl)-5-methyl-oxazol-4-yl]-ethyl ester 
• 876618-53-0 1-{4'-[4-(2-hydroxy-ethyl)-5-methyl-oxazol-2-yl]-biphenyl-3-yl}-ethanone 
• 328918-88-3 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid ethyl ester 
• 328918-26-9 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid 
• 328918-90-7 2-(4-{2-[2-(4-bromophenyl)-5-methyloxazol-4-yl]ethoxy}phenoxy)-2-methylpropionic acid ethyl ester 
• 328918-91-8 2-(4-bromophenyl)-5-methyl-4-vinyloxazole 

Relevant articles and documents

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly